

Objectives and scope

Innovations & Thérapeutiques en Oncologie (ITO) is a bimonthly French-language peer-reviewed journal that publishes a wide range of articles on innovative developments in oncology. The journal's mission is to provide knowledge of innovations in oncology, focusing not only on therapeutic innovations, but also on diagnostic, organizational and educational ones.

Audience

Oncologists.

Editorial Board

Editor-in-Chief

Jean-Pierre Delord (Oncopole Claudius Regaud, Toulouse)

Scientific adviser

Jacques Robert (Université de Bordeaux, Bordeaux)

The full list of the journal's editorial board is available online: <https://www.jle.com/en/revues/ito/comite>

Introduction

The following instructions are in English. *Pour la version française de ces instructions aux auteurs, veuillez consulter le lien suivant :* https://www.jle.com/fr/revues/ito/espace_auteur

Submission address

Manuscripts should be sent to: marine.riviere@jle.com.

Peer review

The journal uses a double-blind peer review process. Each article is initially evaluated by the Editor-in-Chief and Associate Editors to ensure that the content is appropriate for the journal. If the article is found to be appropriate, it is anonymised and sent to at least two independent expert reviewers to assess its scientific quality. The editor-in-chief makes the final decision as whether to accept or reject the article. For more information on the evaluation of articles : <https://www.jle.com/en/peer-review-policy>

Ethical rules

Innovations & Thérapeutiques en Oncologie is an independent peer-reviewed journal and its distribution is linked to subscriptions. The journal is a member of the Syndicat de la presse et de l'édition des professions de santé (SPEPS).

The publisher John Libbey Eurotext joined to the charter for continuing medical education through writing of the National Union of the Medical Press and Health Professions (SNPM) and follows its rules (charter available on request).

Protection of participants in research studies

Each research article submitted should include a statement that the study has obtained ethical approval (or a statement that it was not required and why), including the name of the ethics committee(s) or institutional review board(s).

Authors must ensure that the conduct and publication of research involving human data is in accordance with the Declaration of Helsinki as revised in 2013 (<https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects>).

All authors must have approval to conduct research from an independent local, regional or national human protection committee (e.g. ethics committees, institutional review board). If there is any doubt as to

whether the research was conducted in accordance with the Declaration of Helsinki, the authors should explain the rationale for their approach and demonstrate that the local, regional or national review board has explicitly approved the questionable aspects of the study. Approval by a responsible review board does not preclude the writers from having their own judgement as to whether the conduct of the research was appropriate.

In the case of animal experiments, the authors should indicate whether national and institutional guidelines for the care and use of laboratory animals were followed.

Patient consent and confidentiality

Any manuscript containing personal data of patients must comply with the AVR and ensure anonymisation, consent and confidentiality of the patient. Any manuscript that does not comply with the requirements set out in this policy may be refused.

For more details about the ethical rules followed by the journal, please see: <https://www.jle.com/en/ethical-rules>

Links of interest

Authors are requested to carefully consider the editorial and presentation requirements of the articles. Particular importance is given to the links of interest statement, which is the responsibility of the authors. All the authors' interests related to the article, even if there is none, must be declared on the cover page of the manuscript.

Links of interest will also be the subject of a statement to be completed and signed at the time of proofreading. They will be listed at the end of the article after receipt of this statement.

If there is no reply from the authors, the article will be noted: Links of interest: [First name and surname of the author] has not declared any links of interest in relation to the article.

<https://www.jle.com/en/ethical-rules>

Definition of the role of authors and contributors

Authorship of a biomedical work brings recognition and has important academic, social and financial implications. Authorship also implies responsibility and accountability for published research. The aim is to ensure that any contributor who has made a substantial intellectual contribution to a manuscript is recognised as an author, and that any contributor listed as an author undertakes that they are responsible for what is published.

For more details about the journal's editorial policy, please see: <https://www.jle.com/en/editorial-policy>

Different sections

ITO's main sections are:

- **Editorial:** a column designed to express an opinion on a topical issue;
- **Bridging the Bench-Bed Gap:** to explain the progress of more fundamental knowledge in a field of science applied to treatment and/or diagnosis;
- **Established Innovations:** a section designed to provide an update on innovations with validated clinical applications (therapeutic and/or diagnostic);
- **Ongoing Innovations:** a section devoted to the latest published or presented trial results that could have an impact on practice in the near future;
- **Innovating Clinical Research:** section devoted to clinical cases involving treatment results in rare, uncodified situations that could lead to the development of further studies;
- **Innovation and Healthcare Organization:** news about the impact of innovations on the organizational and economic constraints of care, research and/or teaching.
- **Biotechs and Innovation:** a section to present the range of young biotech companies working in the field of cancer (new diagnostic tools, new therapeutic approaches, etc.).

Presentation of the articles

Language: Papers will normally be written in French. However, non-French speaking authors may submit their work in English. However, as the journal publishes a maximum of one or two articles in English per issue, priority will be given to reviews and original articles.

The title page must include :

- the title in French and English, which should be concise but informative;
- the first name and surname of each author;
- the name and address of the author to whom the correspondence should be addressed with the email address ;

- the full affiliation of each author with address;
- the conflicts of interest (or lack thereof) for each author.

The manuscript must include :

- An abstract in English and French. It should provide a general understanding of the aspects addressed in the article. It should give an overview of the different parts of the article, without going into detail about the results and data given in the body of the article. No references should be called in the abstract.
- Up to 6 key words in English and French. Avoid general terms, plurals and multiple concepts (avoid, for example, "and", "of"). Avoid abbreviations: only abbreviations well established in the field are allowed, and should be expanded. These keywords will be used for indexing purposes.
- Main points: The main points are presented in the form of a short bulleted list of the main elements of the article. The list of key points should be inserted in the manuscript. It contains 3 to 5 points to remember (maximum 100 characters including spaces for each).
- Acknowledgements, if any, of persons, grants, funds, etc. should be placed in a separate paragraph before the references and entitled "Acknowledgements".
- Funding: Details of all sources of funding for the work in question should be given in a separate section entitled 'Funding'. This should appear after the Acknowledgements section. Please clearly identify the entity or entities that provided the underlying financial support for the conduct of the research and/or the preparation of the paper. Please clearly identify the role of the funder(s), if any, in (a) the design of the trial, (b) the collection, analysis and interpretation of the data, (c) the writing of the report, and (d) the decision to submit the article for publication. If the funding source(s) did not contribute, then this should be mentioned.
- References are numbered in order of appearance in the text (Arabic numbers). They appear in square brackets. References should be chosen from journals that are accessible to the widest possible audience (avoid esoteric journals) and should be primarily based on serious general journals rather than on original articles. References cited only in tables or figures are numbered in a sequence established by the first identification of the table in the text. They refer only to published work (including abstracts) or work in press. Journal titles are abbreviated according to the US National Library of Medicine (annually in the January issue of Index Medicus). If there are six or fewer authors, cite them all. If there are more than six, list the first three, followed by "et al".
 - o For journal articles: Names of authors followed by initials of their first names. Title of the article. Name of the journal in italics and abbreviated according to the style of Index Medicus (no punctuation after abbreviations) year; volume: first and last page of the article.
Ex: Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. *J Sci Commun* 2010 ;163 :51-9.
 - o For book chapters: Names and initials of authors. Title of the chapter. In: Names and initials of authors/publishers. Title of book in italics. City: name of the publisher, year of publication: first and last page of the article.
Ex: Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith RZ (eds). *Introduction to the electronic age*, New York: E-Publishing Inc, 2009, p. 281-304.
 - o For books: Names and initials of authors/publishers. Title of book in italics. City: name of publisher, year of publication. Ex: Strunk Jr W, White EB. *The elements of style*. 4th ed. New York: Longman, 2000.
 - o Internet references: you must provide, as a minimum, the full URL and the date on which you last accessed the reference. Any other information, if known (DOI, authors' names, dates, reference to a source publication, etc.) should also be provided.
- Tables are numbered (Arabic numerals) in the order of their first citation in the text. Explanations or miscellaneous notes appear below the tables. Tables should be provided in editable format as separate Word/text documents. PDF is not an acceptable format for tables. Footnotes or captions are preferable to long explanatory texts. Notes should be identified by superscript letters and placed immediately below the table. Abbreviations and acronyms used on the table are defined in the legend, and the table text should be translated if it is in English.
- Figures are numbered (Arabic numerals) in the order of their first citation in the text. Figures must be submitted in JPEG or TIFF format with a minimum resolution of 300 dpi. Drawings or diagrams must be submitted as Powerpoint® or Word® files. Letters, numbers or symbols must be clear and of sufficient size to make each element perfectly legible. Titles or detailed explanations are not included in the illustration.

Captions are typed double-spaced on a separate page. They should be concise but understandable without having to read the text. Abbreviations and acronyms used in the figure are defined in the legend, and the text of the figure should be translated if it is in English. Do not provide files optimised for on-screen use (e.g. GIF, BMP, PICT, WPG), as these formats usually have too few pixels and a limited colour set.

- **Medicines and devices:** Medicines are identified by the generic name (international non-proprietary name) without the initial capital letter. The speciality name may be mentioned in brackets with an initial capital letter, followed by the symbol ® and the name of the pharmaceutical company if the medicine is not well known. The trade name of a device is followed by the name of the manufacturer or distributor in brackets.
- **Abbreviations and symbols:** The full term precedes the abbreviation when it first appears in the text (unless it is an international unit of measurement). Their use must be consistent and invariable throughout the article. Abbreviations are not allowed in titles, intertitles or abstracts. A complete list of abbreviations used is given on a separate sheet at the end of the manuscript. It is advisable to use the minimum number of abbreviations and never when a term is used less than 3 times.
- **Third party material:** In the event that some of the illustrations are produced by third parties, whether or not they have already been published, the author undertakes to obtain from them all the necessary authorisations for the integration of these illustrations into the article and for their use in this form. He/she will communicate these authorisations for reproduction with his/her manuscript.
These permissions are generally issued via the website <https://www.copyright.com> (see the "Get permission" button available for each article). They may be subject to a fee, which is always payable by the author.
If you wish to include figures, images or extracts from previously published articles, it is your responsibility to obtain permission to do so. All material must be properly referenced and you must have the written consent of the copyright holder (this may be the publisher rather than the author). This includes your own previously published material, if you are not the copyright holder.

Editorial follow-up

The proofs will be sent to the corresponding author by e-mail as a PDF file, together with a transfer of rights agreement and a declaration of interest to be filled in individually by each author. Corrections and other documents must be returned by the corresponding author within five working days of receipt of the proof, by e-mail (marine.riviere@jle.com; isabelle.rouxel@jle.com).

If this deadline is not met, the editorial office may take over responsibility for proofreading.

The corrected proof is available online, in prepublication, less than a week after the corrections have been sent, on the publisher's website, under the heading Forthcoming articles: <https://www.jle.com/en/revues/ito/aop.phtml>

Offprints and copies

After the publication of the printed issue, an electronic PDF reprint is sent to the corresponding author by e-mail.

It is possible to order offprints for a fee at the time of proofreading. You will then be given a price list according to the number of pages.

A free copy of the issue is sent to the corresponding author upon request during the proofreading process.

Archiving policy and open access

Authors can disseminate their research in different models.

For more information on content access policies, see the link to Sherpa Romeo: <https://v2.sherpa.ac.uk/id/publication/41824>

In the case of open access articles, permission for third party (re)use is defined according to the Creative Commons user licences defined below.

Whichever publication method you choose, the journal will apply the same peer review criteria and acceptance standards.

Creative Commons Attribution - No Commercial Use - No Derivative Works (CC BY-NC-ND) Non-commercial use licence: allows users to distribute and copy the article, and to include it in a collective work (e.g. an anthology), provided that they credit the author(s) and do not alter or modify the article

Publication fee: the open access publication fee is EUR 400 excluding VAT.

PUBLISHER :

Publisher: John Libbey Eurotext 30A, rue Berthollet
94110 Arcueil, France
Tel: 01 46 73 06 60 - Fax: 01 40 84 09 99
Director of publication: Gilles Cahn

To contact our team and answer your requests, remarks, questions:

Editor:

Marine RIVIÈRE

Tel: +33 (0)7 63 58 96 21

marine.riviere@jle.com

Electronic or printed offprints:

Isabelle ROUXEL

Tel: +33 (0)7 63 58 96 22

isabelle.rouxel@jle.com

Publishing contracts and copyright:

Anne MAURI

Tel: +33 (0)7 63 59 03 71

anne.mauri@jle.com

Subscriptions and marketing:

Arnaud COBO

Tel: +33 (0)7 63 59 03 35

arnaud.cobo@jle.com

Classifieds:

Corinne SALMON

Tel: +33 (0)7 63 59 04 06

corinne.salmon@jle.com

Advertising:

David LAIFER

Tel: +33 (0)7 63 59 03 94

david.laifer@jle.com

Supplements/Partnerships/Reprints:

Noëlle CROISAT

Tel: +33 (0)7 63 59 03 68

noelle.croisat@jle.com

Claire VASSET

Tel: +33 (0)7 63 58 96 19

claire.vasset@jle.com

Congresses and scientific meetings:

Valérie BERLAND

Tel: +33 (0)7 63 59 03 21

valerie.berland@jle.com

Reproduction rights:

Anne CHEVALIER

Tel: +33 (0)7 63 59 03 46

anne.chevalier@jle.com

Further information can be obtained from the following address

Innovations & Thérapeutiques en Oncologie Journal - Editorial Office

30A rue Berthollet

94110 Arcueil

Tel: +33 (0)1 46 73 06 60

contact@jle.com